Fig. 7

HSCs are activated after incubated with MBP-CssPLA2. The marker of the activation, α-SMA of the HSCs, was measured after incubated with 25 μg/ml MBP, 25 μg/ml MBP-CssPLA2 and PBS, respectively. Two more groups, the group of cells incubated with 10 μg/ml MBP-CssPLA2 and the group of cells incubated with both 25 μg/ml MBP-CssPLA2 and 5 μM JNK inhibitor (SP600125) were added to detect whether the activation of hepatic stellate cells by MBP-CssPLA2 was dose-dependent and whether the activation was related to activation of the JNK signalling pathway. a Lane 1: HSCs incubated with 25 μg/ml MBP; Lane 2: HSCs incubated with 25 μg/ml MBP-CssPLA2; Lane 3: HSCs incubated with PBS. b Lane 1: HSCs incubated with 25 μg/ml MBP; Lane 2: HSCs incubated with 10 μg/ml MBP-CssPLA2; Lane 3: HSCs incubated with 25 μg/ml MBP-CssPLA2; Lane 4: HSCs incubated with PBS; Lane 5: HSCs incubated with both 25 μg/ml MBP-CssPLA2 and 5 μM JNK inhibitor (SP600125). c Relative quantitative western blot analysis of α-SMA was performed to compare the difference between experimental group and control group. Statistical analysis were conducted with unpaired t-test